16 September 2026 editorial review · Trial
PANORAMA — bihormonal artificial pancreas after total pancreatectomy: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Located publisher-deposited primary ADA abstract 1257-OR (DOI10.2337/db26-1257-or) through Crossref. Corrected34 randomized / 20 in the primary analysis, time below range 0.9% versus 1.2% and nonsignificant difference. Removed uncorroborated25-person denominator and seven attributed discontinuations. Pancreatic diabetes explicitly distinguished from autoimmuneT1D; conference abstract remains limited.
Registry: NCT06346366; UNKNOWN; updated 2024-04-04; enrollment 40 (ESTIMATED); results not posted.
Endpoint comparison: Time in range (During open and closed loop treatment (both 3 months)).
Sources for this record: 1257-OR: Glucose Control during Three-Month Treatment with a Bihormonal Artificial Pancreas vs. Current Diabetes Care following Total Pancreatectomy (PANORAMA) (conference); PANORAMA randomized crossover trial: study protocol (peer-reviewed); NCT06346366: study record (registry).
Limits: No full peer-reviewed outcome report was identified for the current study; a conference abstract cannot resolve unreported participant-level safety or attrition.